Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Eur J Med Chem
; 150: 366-384, 2018 Apr 25.
Article
in En
| MEDLINE
| ID: mdl-29544149
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyridines
/
Pyrimidines
/
Benzamides
/
Acrylamides
/
Leukemia
/
Hypereosinophilic Syndrome
/
Receptor, Platelet-Derived Growth Factor alpha
/
Drug Discovery
/
Antineoplastic Agents
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur J Med Chem
Year:
2018
Document type:
Article